In addition, a recent Phase I trial demonstrated that CD16-CR T cells, when administered alongside rituximab to patients with relapsed or refractory CD20-positive B cell lymphoma, were tolerated well with limited toxicity [24]. This evidence concerns the gene FCGR3A and B-cell non-Hodgkin lymphoma.